or Try an Advanced Search...

    Technical Analysis for GHRS - GH Research PLC

    Grade Last Price % Change Price Change
    B 12.84 0.78% 0.10
    GHRS closed down 2.15 percent on Wednesday, May 15, 2024, on 19 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical GHRS trend table...
    Date Alert Name Type % Chg
    Upper Bollinger Band Walk Strength 0.78%
    Earnings Movers Other 0.78%
    Outside Day Range Expansion 0.78%
    Gapped Up Strength 0.78%
    Overbought Stochastic Strength 0.78%
    Upper Bollinger Band Touch Strength 0.78%
    Upper Bollinger Band Walk Strength -1.38%
    Inside Day Range Contraction -1.38%
    Above Upper BB Strength -1.38%
    Overbought Stochastic Strength -1.38%
    Older End-of-Day Signals for GHRS ...

       Recent Intraday Alerts

    Alert Time
    Up 1% about 3 hours ago
    60 Minute Opening Range Breakdown 1 day ago
    Upper Bollinger Band Resistance 1 day ago
    Rose Above Previous Day's High 1 day ago
    Rose Above Upper Bollinger Band 1 day ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    GHRS Chart by TradingView
    Basic chart:

    Profile

    GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate that is in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was founded in 2018 and is based in Dublin, Ireland.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Psychoactive Drugs Entheogens Treatment Resistant Depression Psychiatric And Neurological Disorders N Dimethyltryptamine

    Is GHRS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 10 Wall Street Analysts Predict a 166.89% Upside in GH Research (GHRS): Here's What You Should Know
    Mar 5 How Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28%
    Mar 1 GH Research: This European Biotech Company Reports Full Year 2023 Financial Results And Business Updates
    Feb 29 GH Research GAAP EPS of -$0.68
    Feb 29 GH Research Reports Full Year 2023 Financial Results and Provides Business Updates
    Jan 27 Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
    Jan 18 GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression
    Jan 16 Can GH Research PLC (GHRS) Climb 488.72% to Reach the Level Wall Street Analysts Expect?
    Jan 12 Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
    Jan 7 Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More
    See more GHRS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 14.64
    52 Week Low 5.05
    Average Volume 102,576
    200-Day Moving Average 8.89
    50-Day Moving Average 10.96
    20-Day Moving Average 11.65
    10-Day Moving Average 12.21
    Average True Range 0.65
    RSI (14) 64.41
    ADX 48.44
    +DI 32.15
    -DI 6.36
    Chandelier Exit (Long, 3 ATRs) 11.40
    Chandelier Exit (Short, 3 ATRs) 12.25
    Upper Bollinger Bands 13.18
    Lower Bollinger Band 10.13
    Percent B (%b) 0.86
    BandWidth 26.14
    MACD Line 0.55
    MACD Signal Line 0.43
    MACD Histogram 0.1201
    Fundamentals Value
    Market Cap 662.74 Million
    Num Shares 52 Million
    EPS -0.79
    Price-to-Earnings (P/E) Ratio -16.13
    Price-to-Sales 0.00
    Price-to-Book 1.84
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 13.75
    Resistance 3 (R3) 13.84 13.59 13.58
    Resistance 2 (R2) 13.59 13.33 13.54 13.53
    Resistance 1 (R1) 13.16 13.17 13.04 13.08 13.47
    Pivot Point 12.91 12.91 12.85 12.87 12.91
    Support 1 (S1) 12.49 12.65 12.36 12.40 12.01
    Support 2 (S2) 12.24 12.49 12.19 11.95
    Support 3 (S3) 11.81 12.24 11.90
    Support 4 (S4) 11.73